Development of a upar-targeting antibody-drug conjugate (ADC) for pancreatic adenocarcinoma

Active Grant Awarded

Award ID
R43CA309866
Recipient
Awarding agency
Obligated
$399,896

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 24% complete
Place of performance
New York, NY 10014, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Cancer Institute, within the Department of Health and Human Services, awarded Traverse Biotech II Inc. $399,896 under Grant R43CA309866 on August 26, 2026, through the Cancer Treatment Research program (CFDA 93.395). The award funds Phase I development of TB-UA-1, a first-in-class antibody-drug conjugate targeting urokinase plasminogen activator receptor (uPAR) for pancreatic ductal adenocarcinoma. The source states that the Phase I work will construct and evaluate novel anti-uPAR ADC constructs built from anti-uPAR antibodies 3C6 and 2G10, attached to cytotoxic payloads using the recipient's proprietary INSIDEO bioconjugation technology, and that leading constructs will then be evaluated.

The recipient is a woman-owned small business based in New York, New York (UEI JJUSGRQS7RM5). The award's ultimate completion date is August 31, 2027, and the place of performance is New York, NY 10014, USA. The assistance type is a grant, and the vendor profile identifies it as an SBIR Phase I award. The Cancer Treatment Research program includes Small Business Innovation Research support intended to increase small business participation in federal research and development and the private-sector commercialization of federally derived innovations.

Description

Abstract
Traverse biotech is developing TB-UA-1, a first-in-class antibody-drug conjugate (ADC) targeting urokinase plasminogen activator receptor (UPAR) for the treatment of pancreatic ductal adenocarcinoma (PDAC). PDAC remains one of the deadliest malignancies, characterized by a dismal 5-year survival rate of 9-10% due to late- stage diagnosis, limited therapeutic efficacy, and profound resistance to existing treatments such as folfirinox and gemcitabine/NAB-paclitaxel. PDAC is a highly fibrotic and immune-excluding tumor microenvironment where immunotherapies, such as checkpoint inhibitors, are unable to impact immune cells within the tumor and therefore offer little to no clinical outcome benefits. TB-UA-1 targets UPAR, a cell surface receptor overexpressed on the surface of PDAC tumor cells and associated stromal components, including tumor-associated macrophages and cancer-associated fibroblasts. Importantly, UPAR expression is negligible in normal pancreatic tissue, thus minimizing on-target toxicity risks. This dual expression of UPAR on both PDAC tumor cells and stromal components, positions UPAR as an ideal antigen for targeted ADC therapy. We have selected well-validated human anti-UPAR antibodies (3C6 and 2G10) with proven specificity, high affinity, and efficient receptor-mediated internalization into UPAR-expressing cancer cells. These antibodies will be coupled with our proprietary bioconjugation technology (INSIDEÒ), that enables stable and controlled attachment of cytotoxic payloads. This results in optimized ADC stability, drug-to-antibody ratio homogeneity, and ultimately therapeutic efficacy. In this phase I, we will first construct and evaluate novel anti-UPAR ADC constructs built from well-characterized anti-UPAR antibodies with known binding and anti-cancer properties and using inside technologyò. Leading UPAR-ADC constructs will be evaluated and rank-ordered based on efficacy against UPAR-expressing PDAC cell lines. The best performing UPAR-ADC, TB-UA-1, will be evaluated for efficacy in an industry-standard preclinical mouse xenograft model of PDAC. This comprehensive approach will result in human anti-UPAR-ADC product candidate that will be advanced into a future phase II application and non-clinical studies with the ultimate goal of clinical entrance to address the significant unmet medical need in PDAC.

Quick answers

Who received award R43CA309866?

R43CA309866 was awarded to Traverse Biotech II Inc. by National Cancer Institute (National Institutes of Health) on August 26, 2026.

How much is award R43CA309866 worth?

$399,896 has been obligated on R43CA309866.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award